Company
Headquarters: The Woodlands, TX, United States
Founded: The Woodlands, TX, 1995
Employees: 87
CEO: Mr. Lonnel Coats
$414.3 Million
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $2.3 M |
| EBITDA | $-185,360,496 |
| Gross Profit TTM | $1.1 M |
| Profit Margin | 92.94% |
| Operating Margin | -4011.77% |
| Quarterly Revenue Growth | 4608.30% |
Lexicon Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: LXRX wb_incandescent
Stock: FSX: LX31 wb_incandescent
Lonnel Coats, president and chief executive officer Brian P. Zambrowicz, E VP & Chief Scientific Officer Jeffrey L. Wade, E VP of Corporate Development & Chief Scientific Officer Alan J. Main, E VP of Pharmaceutical Research Pablo Lapuerta, E VP of Clinical Development & Chief Medical Officer James F. Tessmer, VP of Finance and Accounting